Opus Genetics, Inc.: 10-Q filed 2012-05-09
What Opus Genetics, Inc. reported in its quarterly report filed 2012-05-09 (fiscal Q1 2012): 19 published measures, 53 facts as tagged in accession 0001140361-12-023967.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-05-09
- Fiscal period
- fiscal Q1 2012
- Accession
- 0001140361-12-023967 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Opus Genetics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 11,709,492 | USD | |
| At 2011-12-31 | 13,689,648 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 3,051,982 | USD | |
| At 2011-12-31 | 2,983,518 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 8,657,510 | USD | |
| At 2011-12-31 | 10,706,130 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 8,101,112 | USD | |
| At 2011-12-31 | 9,861,488 | USD | |
| At 2011-03-31 | 20,513,075 | USD | |
| At 2010-12-31 | 12,340,239 | USD | |
| At 2001-03-18 | 0 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -2,139,794 | USD | 91 |
| 2001-03-19 to 2012-03-31 | -59,224,407 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | -4,436,161 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 0 | USD | 91 |
| 2001-03-19 to 2012-03-31 | 0 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | 0 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 0 | USD | 91 |
| 2001-03-19 to 2012-03-31 | 66,178,583 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | 13,556,234 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 156,134 | USD | 91 |
| 2001-03-19 to 2012-03-31 | -4,160,143 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | -2,957,563 | USD | 90 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 0 | USD | 91 |
| 2001-03-19 to 2012-03-31 | 0 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | 0 | USD | 90 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 83,821 | USD | |
| At 2011-12-31 | 94,542 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 91,174 | USD | 91 |
| 2001-03-19 to 2012-03-31 | 5,668,803 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | 201,988 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -1,884,182 | USD | 91 |
| 2001-03-19 to 2012-03-31 | -63,858,322 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | -3,913,340 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 10,350,040 | USD | |
| At 2011-12-31 | 12,163,341 | USD |
Common-stock repurchase payments
Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 0 | USD | 91 |
| 2001-03-19 to 2012-03-31 | 28,410 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | 0 | USD | 90 |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 1,884,182 | USD | 91 |
| 2001-03-19 to 2012-03-31 | 63,858,322 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | 3,913,340 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 1,042,700 | USD | 91 |
| 2001-03-19 to 2012-03-31 | 32,928,303 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | 2,717,527 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 95,345,656 | shares | |
| At 2011-12-31 | 95,345,656 | shares |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 728,172 | USD | 91 |
| 2001-03-19 to 2012-03-31 | 28,075,167 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | 1,109,172 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -255,612 | USD | 91 |
| 2001-03-19 to 2012-03-31 | 4,633,915 | USD | 4031 |
| 2011-01-01 to 2011-03-31 | -522,821 | USD | 90 |
Inspect the source
- Entity
- Opus Genetics, Inc. / CIK 0001228627
- Captured
- 2026-09-20T07:46:24.028Z
- SEC response SHA-256
59b3f548361fa5c66fb8bd927bac9bc7dc8822bcce158860c7c4d77974af0a92
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001228627.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))